Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.
The level of fetal hemoglobin (HbF) modifies the severity of the common β-globin disorders. Knowledge of the normal mechanisms that repress HbF in the adult stage has remained limited until recently despite nearly 3 decades of molecular investigation, in part because of imperfect model systems. Recent studies have provided new insights into the developmental regulation of globin genes and identified specific transcription factors and epigenetic regulators responsible for physiologic silencing of HbF. Most prominent among these regulators is BCL11A, a transcriptional repressor that inhibits adult-stage HbF expression. KLF1 and c-Myb are additional critical HbF-regulating erythroid transcription factors more broadly involved in erythroid gene expression programs. Chromatin modifiers, including histone deacetylases and DNA methyltransferases, also play key roles in orchestrating appropriate globin gene expression. Taken together, these discoveries present novel therapeutic targets for further consideration. Although substantial hurdles remain, opportunities are now rich for the rational design of HbF inducers.
Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.
Daniel E
DE
Bauer
Sophia C
SC
Kamran
Stuart H
SH
Orkin
D000328:Adult; D005319:Fetal Hemoglobin / Q000235:genetics* / Q000378:metabolism*; D006453:Hemoglobinopathies / Q000628:therapy; D006801:Humans; D058990:Molecular Targeted Therapy; D015533:Transcriptional Activation
D005319:Fetal Hemoglobin